BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
OSENVELT (denosumab-bmwo) by Celltrion is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2025.
Drug data last refreshed 11h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OSENVELT (denosumab-bmwo) is a monoclonal antibody biosimilar approved February 28, 2025, that blocks RANK ligand to inhibit bone resorption. It is indicated for treatment of osteoporosis and other bone-related conditions where osteoclast inhibition is therapeutic. The drug targets patients requiring injection-based RANK ligand inhibition therapy.
Growth
Recent market entry positions OSENVELT in high-growth phase with opportunity for brand expansion, though commercial team size remains limited at 3 linked positions.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Celltrion is hiring 2 roles related to this product
Worked on OSENVELT at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.